CLTX News 5.74 Celsus Therapeutics Plc. (CLTX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celsus Therapeutics Plc. (CLTX) 5.74 $CLTX

Celsus Therapeutics Plc Announces Formation of New Dermatology Scientific Advisory Board
GlobeNewswire - Mon Apr 07, 6:30AM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today the formation of a new Dermatology Scientific Advisory Board (SAB). The SAB is comprised of:

Celsus Therapeutics Plc to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief Executive Officer of Celsus, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8th, at 3:40 p.m. Eastern Daylight Time at the Westin Grand Central Hotel in New York.

Celsus Therapeutics Provides Year End 2013 Financial Results and Corporate Highlights
GlobeNewswire - Mon Mar 24, 3:05PM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, today announced its financial results and provided a review of the twelve month period ended December 31, 2013.

Celsus Therapeutics Provides Update on MRX-6 From FDA Pre-IND Meeting
GlobeNewswire - Tue Mar 11, 3:05PM CDT
-- Celsus completes Type B pre-IND meeting with FDA for MRX-6 cream in atopic dermatitis

Contact Dermatitis - Pipeline Review, H2 2013 Report
M2 - Mon Feb 17, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/hxk6vr/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2013" report to their offering. 'Contact Dermatitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Contact Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Contact Dermatitis. Scope - A snapshot of the global therapeutic scenario for Contact Dermatitis. - A review of the Contact Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Contact Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Contact Dermatitis Overview Therapeutics Development Pipeline Products for Contact Dermatitis - Overview Pipeline Products for Contact Dermatitis - Comparative Analysis Contact Dermatitis - Therapeutics under Development by Companies Contact Dermatitis - Pipeline Products Glance Clinical Stage Products Early Stage Products Contact Dermatitis - Products under Development by Companies Contact Dermatitis - Companies Involved in Therapeutics Development Contact Dermatitis - Therapeutics Assessment Drug Profiles MRX-6 - Drug Profile RTU-1096 - Drug Profile MAM-06.301 - Drug Profile AN-3485 - Drug Profile HPT-721 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned R-Tech Ueno, Ltd. Marinomed Biotechnologie GmbH Anacor Pharmaceuticals, Inc. Celsus Therapeutics Plc Hapten Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/hxk6vr/contact About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Celsus Therapeutics to Present at the 2014 BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 06, 6:30AM CST
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief Executive Officer of Celsus, will present at the 2014 BIO CEO & Investor Conference on Monday, February 10, at 4:00 p.m. Eastern Standard Time at the Waldorf Astoria in New York.

Celsus Therapeutics Announces the Closing of $9.2 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional ADSs
GlobeNewswire - Wed Feb 05, 3:05PM CST
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today the closing of its previously announced public offering of 1,533,333 American Depository Shares ("ADSs" on the NASDAQ Capital Market at a price of $6.00 per ADS. The final number of ADSs includes the full exercise by the underwriter of its option to purchase 200,000 additional ADSs. Each ADS represents ten of the Company's ordinary shares. The gross proceeds from this offering, including from the exercise of the over-allotment option, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $9,200,000. Celsus' ADSs are listed on the NASDAQ Capital Market under the trading symbol "CLTX" and began trading there on January 31, 2014.

Celsus Therapeutics Announces Pricing of Public Offering and Listing on NASDAQ
GlobeNewswire - Thu Jan 30, 4:32PM CST
Celsus Therapeutics Plc (Nasdaq:CLTX) (formerly OTCQB:CLSXD), an emerging growth, development-stage biotech company, announced today the pricing of its public offering of 1,333,333 American Depository Shares ("ADSs" on the NASDAQ Capital Market at a price of $6.00 per ADS. Each ADS represents ten of the Company's ordinary shares. The gross proceeds from this offering, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $8,000,000. The offering is expected to close on or about February 5th, 2014, subject to customary closing conditions. Celsus also granted the underwriter a 30-day option to purchase 200,000 additional ADSs at the public offering price to cover over-allotments, if any.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

XKIG Bolsters Northwest with Jensen's Acquisition

Updated Category News Views 44

Stepping Up the Game in the Pacific Northwest Well, here we see another classic example of a shrewd move in the infrastructure sector. XKIG, a name known to those who keep an eye on critical infrastructure services for utilities, has decided to widen its footprint with a strategic grab of Jensen's Tree Service, Inc. They’re setting up shop even deeper in the Pacific...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 193

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 85

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 74

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 104

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 246

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 126

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading

Top 5 Most Recently Viewed Articles

RegScale Secures FedRAMP High Authorization: A Game-Changer

Updated Category News Views 263

RegScale Secures FedRAMP High Authorization RegScale, utilizing its innovative Continuous Controls Monitoring platform, has reached the notable milestone of obtaining FedRAMP High Authorization, demonstrating a significant advancement in compliance and risk management within the government sector. This achievement showcases RegScale's commitment to enhancing security...

Continue Reading
SiriusXM Improves Financial Guidance Amid Digital Growth

Updated Category News Views 214

SiriusXM Holdings Inc Experiences Stock Surge SiriusXM Holdings Inc (NASDAQ:SIRI) saw its stock prices climb significantly following the release of its fiscal third-quarter results. Investors responded positively as the company’s future outlook showed promise for expansion. Positive Financial Results The report revealed a subscriber revenue of $1.63 billion for the...

Continue Reading
Explore Top Free AI Image Translators for Your Needs

Updated Category News Views 288

Unlocking the Power of Image Translation Translating text from images is a crucial task in today’s digital world. Whether you need to read signs, understand menus, interpret social media posts, or analyze product reviews, having a reliable image translator can make a significant difference. The right tools not only improve accuracy but also support multiple languages,...

Continue Reading
Exciting Collaboration Unveiled: REESE'S and OREO Join Forces

Updated Category News Views 240

An Exciting New Collaboration The anticipation has been palpable among fans of REESE'S and OREO, and now, the moment has arrived. These iconic brands, celebrated for their unique flavors, are thrilled to present a delectable collaboration that combines their most popular offerings. This partnership responds directly to the enthusiasm and demand expressed by fans....

Continue Reading
Innovative Clinical Research Enhances Care for Cancer Patients

Updated Category News Views 440

Innovative Research at Florida Cancer Specialists Clinical research at Florida Cancer Specialists & Research Institute is making significant strides in expanding treatment options for patients dealing with gastrointestinal and genitourinary cancers. This knowledgeable institute is at the forefront of developing and presenting vital research that contributes to improved...

Continue Reading